Comparative Pharmacology
Head-to-head clinical analysis: IBUPROFEN versus INDICLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROFEN versus INDICLOR.
Ibuprofen vs INDICLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription.
200-800 mg orally every 6-8 hours; maximum 3200 mg/day.
INDICLOR is not a recognized drug; no standard dosing available.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours; no accumulation with repeated dosing in normal renal function.
Terminal elimination half-life is 12 hours (range 10-15 hours) in patients with normal renal function; prolonged in renal impairment (up to 25 hours in severe cases).
Clinical Note
moderateIbuprofen + Gatifloxacin
"Ibuprofen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateIbuprofen + Rosoxacin
"Ibuprofen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateIbuprofen + Levofloxacin
"Ibuprofen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateIbuprofen + Trovafloxacin
"Ibuprofen may increase the neuroexcitatory activities of Trovafloxacin."
Renal excretion of conjugated metabolites (about 90% as glucuronide and sulfate conjugates, <10% as unchanged drug); minor biliary/fecal elimination (<5%).
Primarily renal excretion (approximately 70% unchanged drug); biliary/fecal excretion accounts for about 10-15% as metabolites.
Category D/X
Category C
NSAID
NSAID